-  - Var. - Volume Denaro- Lettera- Capitalizzazione di mercato Dividend Y. Rapporto P/E
-EUR - -
Fatturato: -
-Quantità in denaro: - -Quantità in lettera: - 149.13 mill.EUR - -

Descrizione business

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on outlicensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Oliver R. Baumann
Consiglio di amministrazione
Carl von Halem, Dr. Frank Plöger, Beat Kläui, Christian Faber, Dr. Alexander Zink
Consiglio di sorveglianza
David L. Deck, Mark S. Müller, Désirée Dosch, Dr. Norbert Windhab, Oliver R. Baumann
 

Dati aziendali

Name: Xlife Sciences AG
Indirizzo: Klausstrasse 19,CH-8008 Zürich
Telefono: +41-44385-8460
Fax: -
E-mail: info@xlifesciences.ch
Internet: https://www.xlifesciences.ch/
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: -
Data dell'IPO: -

Rapporti con gli investitori

Name: Elena Sachs
IR telefono: +41-44385-8462
IR Fax: -
IR e-mail: ir@xlifesciences.ch

Company calendar

CW 17 | 25/04/2025 Annual Report
CW 26 | 24/06/2025 General Shareholder Meeting
CW 39 | 23/09/2025 Interim Report 2nd Quarter/6 Months
 

Principali azionisti

Altri
 
48.94%
David L. Deck
 
23.58%
Gilbert Schöni
 
20.30%
Oliver R. Baumann
 
7.18%